Ads
related to: squamous cell carcinoma
Search results
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $66.29 Consensus Target Price from Analysts
ETF DAILY NEWS· 2 days agoJanux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) has been given an average recommendation of “Moderate Buy” by the eight brokerages that are presently covering the firm, MarketBeat reports ...
Ad
related to: squamous cell carcinoma